Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$108.75 -0.6%	$105.71	$75.56 ▼ $139.13	$5.43B	0.51	778,016 shs	354,313 shs
CRSP CRISPR Therapeutics	$58.82 +2.6%	$52.73	$30.04 ▼ $71.13	$5.35B	1.8	2.62 million shs	4.89 million shs
NUVL Nuvalent	$76.80 -1.8%	$78.94	$55.53 ▼ $113.51	$5.51B	1.3	544,256 shs	249,993 shs
SDGR Schrodinger	$19.45 -2.0%	$21.33	$16.60 ▼ $28.47	$1.43B	1.67	1.16 million shs	4.40 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+3.95%	+5.94%	-2.62%	+2.02%	+28.92%
CRSP CRISPR Therapeutics	+2.24%	+2.71%	+2.56%	+59.37%	+20.00%
NUVL Nuvalent	+2.13%	+1.31%	-7.51%	+10.20%	+9.52%
SDGR Schrodinger	+5.25%	+2.59%	-6.15%	-15.07%	-0.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8383 of 5 stars	4.5	3.0	4.5	2.4	4.2	0.6
CRSP CRISPR Therapeutics	2.9004 of 5 stars	3.3	2.0	0.0	3.2	3.3	0.6
NUVL Nuvalent	2.9361 of 5 stars	4.5	1.0	0.0	1.6	3.3	0.0
SDGR Schrodinger	3.0031 of 5 stars	3.4	2.0	0.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	63.68% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	21.73% Upside
NUVL Nuvalent	3.09	Buy	$119.60	55.73% Upside
SDGR Schrodinger	2.80	Moderate Buy	$31.20	60.41% Upside

Current Analyst Ratings Breakdown

Latest SDGR, NUVL, AXSM, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/21/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.07	N/A	N/A	$1.46 per share	74.49
CRSP CRISPR Therapeutics	$37.31M	143.38	N/A	N/A	$18.81 per share	3.13
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.09 per share	N/A
SDGR Schrodinger	$207.54M	6.88	N/A	N/A	$4.67 per share	4.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	38.56	N/A	-49.88%	-283.22%	-33.06%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	8/14/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	N/A

Latest SDGR, NUVL, AXSM, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
CRSP CRISPR Therapeutics	N/A	16.61	16.61
NUVL Nuvalent	N/A	13.57	13.57
SDGR Schrodinger	N/A	3.30	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CRSP CRISPR Therapeutics	69.20%
NUVL Nuvalent	97.26%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
CRSP CRISPR Therapeutics	4.30%
NUVL Nuvalent	10.20%
SDGR Schrodinger	21.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
SDGR Schrodinger	790	73.38 million	57.97 million	Optionable

SDGR, NUVL, AXSM, and CRSP Headlines

Recent News About These Companies

Schrodinger discontinues SGR-2921 clinical development program

4 hours ago | msn.com

Schrodinger stock plunges after discontinuing key leukemia drug

4 hours ago | investing.com

Schrödinger stops development of blood cancer therapy after two patient deaths

4 hours ago | reuters.com

Schrödinger Stock Plummets After Halting Key Leukemia Drug Program

4 hours ago | msn.com

Schrödinger Announces Discontinuation of SGR-2921 Program

August 14 at 7:38 AM | finance.yahoo.com

Leerink Partnrs Forecasts Increased Earnings for Schrodinger

August 12 at 2:45 AM | americanbankingnews.com

Schrodinger (SDGR) Receives a Buy from Citi

August 11 at 9:36 PM | theglobeandmail.com

Schrodinger, Inc. Earnings Call: Growth Amid Challenges

August 11 at 6:24 AM | theglobeandmail.com

Schrodinger (SDGR) Gets a Buy from Craig-Hallum

August 11 at 6:24 AM | theglobeandmail.com

Leerink Partnrs Lifts Earnings Estimates for Schrodinger

August 11 at 2:43 AM | marketbeat.com

SchrÃ¶dinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Schrödinger, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6, 2025 | seekingalpha.com

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2025 | zacks.com

Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result

August 6, 2025 | finance.yahoo.com

SchrÃ¶dinger (SDGR) Q2 2025 Earnings Transcript

August 6, 2025 | fool.com

Schrödinger Reports Second Quarter 2025 Financial Results

August 6, 2025 | businesswire.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Takes $359,000 Position in Schrodinger, Inc. (NASDAQ:SDGR)

August 6, 2025 | marketbeat.com

Citi Affirms Buy Rating on Schrödinger (SDGR) amid Expanded Collaboration with Ajax Therapeutics

August 5, 2025 | msn.com

Schrodinger (SDGR) to Release Quarterly Earnings on Wednesday

August 5, 2025 | americanbankingnews.com

Universal Beteiligungs und Servicegesellschaft mbH Invests $4.03 Million in Schrodinger, Inc. (NASDAQ:SDGR)

July 29, 2025 | marketbeat.com

ARK Investment Management LLC Has $45.29 Million Stake in Schrodinger, Inc. (NASDAQ:SDGR)

July 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR, NUVL, AXSM, and CRSP Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$108.75 -0.64 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$108.74 -0.01 (-0.01%)

As of 04:30 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics NASDAQ:CRSP

$58.82 +1.49 (+2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$58.75 -0.07 (-0.12%)

As of 04:30 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Nuvalent NASDAQ:NUVL

$76.80 -1.44 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$76.80 0.00 (-0.01%)

As of 04:20 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Schrodinger NASDAQ:SDGR

$19.45 -0.39 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$19.48 +0.03 (+0.15%)

As of 04:27 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time